Agendia (The Netherlands) a commercial-stage molecular diagnostics company focused on gene expression profiling and patient stratification in breast and colon cancers, closed a $25M Series E financing. Participants have included ING, Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures.